Journal
CHEMISTRY & BIOLOGY
Volume 8, Issue 3, Pages 289-299Publisher
CELL PRESS
DOI: 10.1016/S1074-5521(01)00015-1
Keywords
Her2; Hsp90 inhibitor; novel anti-tumor agent; geldanamycin
Categories
Ask authors/readers for more resources
Background: The Hsp90s contain a conserved pocket that binds ATP/ADP and plays an important role in the regulation of chaperone function. Occupancy of this pocket by several natural products (geldanamycin (GM) and radicicol) alters Hsp90 function and results in the degradation of a subset of proteins (i.e. steroid receptors, Her2, Raf). We have used the structural features of this pocket to design a small molecule inhibitor of Hsp90. Results: The designed small molecule PU3 competes with GM for Hsp90 binding with a relative affinity of 15-20 muM. PU3 induces degradation of proteins, including Her2, in a manner similar to GM. Furthermore, PU3 inhibits the growth of breast cancer cells causing retinoblastoma protein hypophosphorylation, G1 arrest and differentiation. Conclusions: PU3 is representative of a novel class of synthetic compounds that binds to Hsp90 and inhibits the proliferation of cancer cells. These reagents could provide a new strategy for the treatment of cancers. (C) 2001 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available